Recommendations for Adult Immunization by the Korean Society of Infectious Diseases, 2023: Minor Revisions to the 3rd Edition

키워드

참고문헌 (88)

1. Choi WS, "Revised adult immunization guideline recommended by the Korean Society of Infectious Diseases, 2014", Infect Chemother, 47, pp.68~79 (2015)
2. Domnich A, "Comparative effectiveness of adjuvanted versus high-dose seasonal influenza vaccines for older adults : a systematic review and meta-analysis", Int J Infect Dis, 122, pp.855~863 (2022)
3. Jackson ML, "Influenza vaccine effectiveness in elderly people", Lancet Infect Dis, 14, pp.1169~1170 (2014)
4. Chang LJ, "Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age : a phase 3 randomized clinical trial", Vaccine, 37, pp.5825~5834 (2019)
5. Essink B, "Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults", Vaccine, 38, pp.242~250 (2020)
6. DiazGranados CA, "Efficacy of high-dose versus standard-dose influenza vaccine in older adults", N Engl J Med, 371, pp.635~645 (2014)
7. Lee JKH, "Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults : a systematic review and meta-analysis", Expert Rev Vaccines, 17, pp.435~443 (2018)
8. Izurieta HS, "Relative effectiveness of influenza vaccines among the United States elderly, 2018-2019", J Infect Dis, 222, pp.278~287 (2020)
9. Izurieta HS, "Comparative effectiveness of influenza vaccines among US medicare beneficiaries ages 65 years and older during the 2019-2020 season", Clin Infect Dis, 73, pp.e4251~e4259 (2021)
10. Keitel WA, "Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons", Arch Intern Med, 166, pp.1121~1127 (2006)
11. Van Buynder PG, "The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine(TIV)in the elderly", Vaccine, 31, pp.6122~6128 (2013)
12. Mannino S, "Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy", Am J Epidemiol, 176, pp.527~533 (2012)
13. Baay M, "A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among older adults", Vaccine, 36, pp.4207~4214 (2018)
14. Grohskopf LA, "Prevention and control of seasonal influenza with vaccines : recommendations of the advisory committee on immunization practices, United States, 2021-22 influenza season", MMWR Recomm Rep, 70, pp.1~28 (2021)
15. Dunkle LM, "Efficacy of recombinant influenza vaccine in adults 50 years of age or older", N Engl J Med, 376, pp.2427~2436 (2017)
16. O Murchu E, "Systematic review of the efficacy, effectiveness and safety of recombinant haemagglutinin seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age", Rev Med Virol, 33, pp.e2331~ (2023)
17. Yun JW, "Cost-effectiveness of influenza vaccine strategies for the elderly in South Korea", PLoS One, 14, pp.e0209643~ (2019)
18. Choi MJ, "Cost-effectiveness of influenza vaccination strategies in adults : older adults aged ≥65 years, adults aged 50-64 years, and at-risk adults aged 19-64 years", Vaccines(Basel), 10, pp.445~ (2022)
19. Lal H, "Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults", N Engl J Med, 372, pp.2087~2096 (2015)
20. Morrison VA, "Long-term persistence of zoster vaccine efficacy", Clin Infect Dis, 60, pp.900~909 (2015)
21. Choi WS, "Disease burden of herpes zoster in Korea", J Clin Virol, 47, pp.325~329 (2010)
22. Choi JK, "The changing epidemiology of herpes zoster over a decade in South Korea, 2006-2015", Vaccine, 37, pp.5153~5160 (2019)
23. Cunningham AL, "Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older", N Engl J Med, 375, pp.1019~1032 (2016)
24. Strezova A, "Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine : interim efficacy, immunogenicity, and safety results up to 10 years after Initial vaccination", Open Forum Infect Dis, 9, pp.ofac485~ (2022)
25. Chen SY, "Incidence of herpes zoster in patients with altered immune function", Infection, 42, pp.325~334 (2014)
26. Choi WS, "Immunity and the burden of herpes zoster", J Med Virol, 86, pp.525~530 (2014)
27. Bastidas A, "Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation : a randomized clinical trial", JAMA, 322, pp.123~133 (2019)
28. Dagnew AF, "Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies : a phase 3, randomised, clinical trial and post-hoc efficacy analysis", Lancet Infect Dis, 19, pp.988~1000 (2019)
29. Dagnew AF, "Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases : a pooled post hoc analysis on two parallel randomized trials", Rheumatology(Oxford), 60, pp.1226~1233 (2021)
30. Grupping K, "Immunogenicity and safety of the HZ", su adjuvanted herpes zoster subunit vaccine in adults previously vaccinated with a live attenuated herpes zoster vaccine, 2017, pp.216, 1343~1351
31. Dagnew AF, "The adjuvanted recombinant zoster vaccine in adults aged ≥65 years previously vaccinated with a live-attenuated herpes zoster vaccine", J Infect Dis, 224, pp.1139~1146 (2021)
32. Mills R, "Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster", Vaccine, 28, pp.4204~4209 (2010)
33. Godeaux O, "Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster : A phase III, non-randomized, open-label clinical trial", Hum Vaccin Immunother, 13, pp.1051~1058 (2017)
34. Tseng HF, "Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population", J Infect Dis, 206, pp.190~196 (2012)
35. Kobayashi M, "Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U. S. adults : updated recommendations of the advisory committee on immunization practices-United States, 2022", MMWR Morb Mortal Wkly Rep, 71, pp.109~117 (2022)
36. Matanock A, "Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years : updated recommendations of the advisory committee on immunization practices", MMWR Morb Mortal Wkly Rep, 68, pp.1069~1075 (2019)
37. Centers for Disease Control, "Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions : recommendations of the Advisory Committee on Immunization Practices(ACIP)", MMWR Morb Mortal Wkly Rep, 61, pp.816~819 (2012)
38. Ermlich SJ, "Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age", Vaccine, 36, pp.6875~6882 (2018)
39. Peterson JT, "Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine", Hum Vaccin Immunother, 15, pp.540~548 (2019)
40. Platt HL, "A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older(PNEU-AGE)", Vaccine, 40, pp.162~172 (2022)
41. Mohapi L, "Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV", AIDS, 36, pp.373~382 (2022)
42. Song JY, "Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years : A randomized phase III trial(PNEU-PATH)", Vaccine, 39, pp.6422~6436 (2021)
43. Essink B, "3. Phase 3 pivotal evaluation of 20-valent pneumococcal conjugate vaccine(PCV20)safety, tolerability, and immunologic noninferiority in participants 18 years and older", Open Forum Infect Dis, 7(Suppl 1), pp.S2~ (2020)
44. Klein NP, "A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age", Vaccine, 39, pp.5428~5435 (2021)
45. Hurley D, "Safety, Tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine(PCV20)in adults 60 to 64 years of age", Clin Infect Dis, 73, pp.e1489~e1497 (2021)
46. Korea Disease Control and Prevention Agency (KDCA), "Epidemiology and management of vaccine preventable disease" (2017), KDCA
47. Heo JY, "Epidemiology of community-acquired pneumonia in the era of extended serotype-covering multivalent pneumococcal conjugate vaccines", Vaccine, 38, pp.7747~7755 (2020)
48. Kim JH, "Adult invasive pneumococcal disease in the Republic of Korea : Risk medical conditions and mortality stratified by age group", Int J Infect Dis, 74, pp.136~144 (2018)
49. Yoon JG, "Persistent serotype 3 and 19A invasive pneumococcal diseases in adults in vaccine era : serotype-dependent difference in ceftriaxone susceptibility", Vaccine, 40, pp.2258~2265 (2022)
50. Mertsola J, "Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults", Clin Infect Dis, 51, pp.656~662 (2010)
51. Booy R, "A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine(Boostrix™)is immunogenic and well tolerated in adults", Vaccine, 29, pp.45~50 (2010)
52. Halperin SA, "Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose", Vaccine, 30, pp.974~982 (2012)
53. Halperin SA, "Randomized controlled trial of the safety and immunogenicity of revaccination with tetanus-diphtheria-acellular pertussis vaccine(Tdap)in adults 10 years after a previous dose", J Pediatric Infect Dis Soc, 8, pp.105~114 (2019)
54. Kovac M, "Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence : An open, phase III, non-randomized, multi-center study", Hum Vaccin Immunother, 14, pp.1977~1986 (2018)
55. Havers FP, "Use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines : updated recommendations of the advisory committee on immunization practices-United States, 2019", MMWR Morb Mortal Wkly Rep, 69, pp.77~83 (2020)
56. Beytout J, "Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults : a placebo-controlled trial", Hum Vaccin, 5, pp.315~321 (2009)
57. Talbot EA, "The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine(Tdap)less than 2 years following previous tetanus vaccination : experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak", Vaccine, 28, pp.8001~8007 (2010)
58. Halperin SA, "Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed(Tdap)4-5 years after a previous dose", Vaccine, 29, pp.8459~8465 (2011)
59. Theeten H, "Primary vaccination of adults with reduced antigen-content diphtheria-tetanus-acellular pertussis or dTpa-inactivated poliovirus vaccines compared to diphtheria-tetanus-toxoid vaccines", Curr Med Res Opin, 23, pp.2729~2739 (2007)
60. Fortner KB, "Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine(Tdap)in pregnant and nonpregnant women", Vaccine, 36, pp.6354~6360 (2018)
61. Sukumaran L, "Association of tdap vaccination with acute events and adverse birth outcomes among pregnant women with prior tetanus-containing immunizations", JAMA, 314, pp.1581~1587 (2015)
62. Meites E, "Human papillomavirus vaccination for adults : updated recommendations of the advisory committee on immunization practices", MMWR Morb Mortal Wkly Rep, 68, pp.698~702 (2019)
63. Laprise JF, "Effectiveness and cost-effectiveness of human papillomavirus vaccination through age 45 years in the United States", Ann Intern Med, 172, pp.22~29 (2020)
64. Van Damme P, "A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men", Vaccine, 34, pp.4205~4212 (2016)
65. Goldstone SE, "Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men : results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial", Lancet Infect Dis, 22, pp.413~425 (2022)
66. Harrison R, "Occupational exposure to human papillomavirus and vaccination for health care workers", Obstet Gynecol, 136, pp.663~665 (2020)
67. "One-dose human papillomavirus (HPV) vaccine offers solid protection against cervical cancer"[URL]
68. Santolaya ME, "Immunogenicity and tolerability of a multicomponent meningococcal serogroup B(4CMenB)vaccine in healthy adolescents in Chile : a phase 2b", 3 randomised, observer-blind, placebo-controlled study, 2012, pp.379, 617~624
69. Rodrigues FMP, "Association of use of a meningococcus group B vaccine with group B invasive meningococcal disease among children in Portugal", JAMA, 324, pp.2187~2194 (2020)
70. Heo JY, "Meningococcal Disease in Korea : an epidemiologic study of the underestimated infectious disease", Infect Chemother, 48, pp.51~53 (2016)
71. "Infectious disease statistics system"[URL]
72. Bae SM, "Serological and genetic characterization of meningococcal isolates in Korea", Jpn J Infect Dis, 61, pp.434~437 (2008)
73. Lee H, "Prevalence and serogroup changes of Neisseria meningitidis in South Korea, 2010-2016", Sci Rep, 8, pp.5292~ (2018)
74. "2021 Meningococcal management guideline"[URL]
75. Kim NH, "Carriage rates and serogroups of Neisseria meningitides in children attending day care centers", Korean J Pediatr Infect Dis, 16, pp.31~39 (2009)
76. Durey A, "Carriage rates and serogroups of Neisseria meningitidis among freshmen in a University dormitory in Korea", Yonsei Med J, 53, pp.742~747 (2012)
77. Hwang IU, "The changes of meningococcal carriage rate and the serogroup in Korean army recruits", J Korean Mil Med Assoc, 41, pp.188~199 (2010)
78. Kim HW, "Characterization of Oropharyngeal Carriage Isolates of Neisseria meningitidis in Healthy Korean Adolescents in 2015", J Korean Med Sci, 32, pp.1111~1117 (2017)
79. Choi H, "Longitudinal study of meningococcal carriage rates in university entrants living in a dormitory in South Korea", PLoS One, 16, pp.e0244716~ (2021)
80. Sulis G, "A comparison of national vaccination policies to prevent serogroup B meningococcal disease", Vaccine, 40, pp.3647~3654 (2022)
81. Sohn WY, "Real-world implementation of 4-component meningococcal serogroup B vaccine(4CMenB) : implications for clinical practices", Expert Rev Vaccines, 21, pp.325~335 (2022)
82. World Health Organization(WHO), "Rabies vaccines : WHO position paper – April 2018", Wkly Epidemiol Rec, 16, pp.201~219 (2018)
83. Rao AK, "Use of a modified preexposure prophylaxis vaccination schedule to prevent human rabies : recommendations of the advisory committee on immunization practices-United States, 2022", MMWR Morb Mortal Wkly Rep, 71, pp.619~627 (2022)
84. "ACIP grading of recommendations assessment, development and evaluation (GRADE) for 2-dose rabies vaccination schedule"[URL]
85. Soentjens P, "Preexposure intradermal rabies vaccination : a noninferiority trial in healthy adults on shortening the vaccination schedule from 28 to 7 days", Clin Infect Dis, 68, pp.607~614 (2019)
86. Strady A, "Antibody persistence following preexposure regimens of cell-culture rabies vaccines : 10-year follow-up and proposal for a new booster policy", J Infect Dis, 177, pp.1290~1295 (1998)
87. Mansfield KL, "Rabies pre-exposure prophylaxis elicits long-lasting immunity in humans", Vaccine, 34, pp.5959~5967 (2016)
88. Yang DK, "Detection of viral infections in wild Korean raccoon dogs(Nyctereutes procyonoides koreensis)", Korean J Vet Res, 57, pp.209~214 (2017)

관련 논문AI추천